Mechanistically, arctigenin decreased the promoter activities of GM-CSF and TSLP via hindering the nuclear translocation of NF-κB p65, and consequently, inhibited STAT3/β-catenin signaling, resulting in decreased proliferation, invasion and stemness of breast cancer cells in vitro and in vivo. The gene discussed is NFKB1; the disease is breast carcinoma.